ARCT Sep 2024 22.500 call
| Previous close | 9.20 |
| Open | 9.20 |
| Bid | 16.30 |
| Ask | 19.50 |
| Strike | 22.50 |
| Expiry date | 2024-09-20 |
| Day's range | 9.20 - 9.20 |
| Contract range | N/A |
| Volume | |
| Open interest | 5 |
Business WireArcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
SAN DIEGO, May 28, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced Arcturus will be presenting Phase 1 results in healthy volunteers and new Phase 1b interim data in CF patients for ARCT-032, an inhaled investigational mRNA therapeutic to tr
GlobeNewswireAchilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
Combines Achilles’ best-in-class AI-driven, tumor-targeting technology with Arcturus’ world-leading self-amplifying mRNA platform Combined technologies have the potential to generate potent and durable T cell responses in pre-clinical IND-enabling studies LONDON, May 22, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced a research collaboration with
PR NewswireNature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announce Nature Communications has published results from an integrated phase 1/2/3a/3b study evaluating the safety, immunogenicity, and efficacy of ARCT, 154, a novel self-amplifying (sa-mRNA) COVID-19 vaccine and the world's first approved sa-mRNA COVID-19 vaccine.
